GlassScriptPhysician profile
Breanna M Sirko
NPI 1487492641
$4,034.96
in general payments reported to CMS, 2019-2025
36 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,550 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $522.13 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $501.69 | 2024-2025 | |
| Lilly USA, LLC | $355.76 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $261.91 | 2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.99 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $235.39 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $188.30 | 2025 | Wegovy |
| Alkermes, INC. | $131.93 | 2024-2025 | Vivitrol |
| Glaxosmithkline, LLC. | $126.02 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $109.41 | 2024-2025 | Auvelity |
| Verona Pharma, INC. | $109.16 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $105.58 | 2024-2025 | Fanapt |
| Lundbeck LLC | $99.71 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $97.34 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $88.60 | 2025 | Inceptiv |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.10 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.55 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.47 | 2024-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $81.70 | 2024-2025 | Freestyle Libre 3 |
| Electromed, INC. | $79.31 | 2024-2025 | Smartvest |
| Vivus LLC | $49.13 | 2025 | Qsymia |
| Boston Scientific Corporation | $47.88 | 2024-2025 | Watchman Access System, Watchman |
| Amgen INC. | $38.31 | 2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $37.76 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Azurity Pharmaceuticals, INC. | $37.02 | 2025 | Azmiro |
| Takeda Pharmaceuticals U.S.A., INC. | $29.74 | 2024-2025 | Trintellix |
| Antares Pharma, INC. | $24.58 | 2024 | Xyosted |
| Paratek Pharmaceuticals, INC. | $24.46 | 2025 | Nuzyra |
| Daiichi Sankyo INC. | $22.39 | 2025 | Injectafer |
| Sumitomo Pharma America, INC. | $21.34 | 2025 | Gemtesa |
| Dexcom, INC. | $19.82 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $19.53 | 2025 | Rexulti |
| Seqirus USA INC | $18.88 | 2025 | Fluad, Flucelvax |
| Supernus Pharmaceuticals, INC. | $16.71 | 2025 | Qelbree |
| Biogen, INC. | $15.70 | 2025 | Spinraza |
| Medicomp INC | $15.66 | 2025 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breanna Sirko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.